Oral insulin collaboration signed
25 Feb 2011 by Evoluted New Media
Biopharmaceutical company Emisphere Technologies has entered into an exclusive Development and License Agreement with Novo Nordisk to develop and commercialise oral formulations of Novo Nordisk’s insulin using their Eligen Technology.
Biopharmaceutical company Emisphere Technologies has entered into an exclusive Development and License Agreement with Novo Nordisk to develop and commercialise oral formulations of Novo Nordisk’s insulin using their Eligen Technology.
|
Insulin pens could die out as agreement to develop oral insulin signed |
Under the agreement, Novo Nordisk is responsible for the development and commercialisation of the product candidate: insulin that could be administered orally to treat diabetes. The treatment will use Emisphere’s Eligen Technology, which uses proprietary, synthetic chemical compounds as carriers. The technology allows delivery of therapeutic molecules without altering the chemical formula or biological integrity.
The agreement includes $57.5m in product development and sales milestone payments to Emisphere – including a minimum $5m in the first year – as well as royalties on sales.
“This is an encouraging agreement on a promising technology for oral administration of proteins,” said Peter Kurtzhals senior vice president of diabetes research unit at Novo Nordisk. “We are delighted to continue working with Emisphere and their Eligen Technology.”
“The agreement has the potential to offer significant new solutions to millions of people with diabetes worldwide, which provides a very strong motivation for the Emisphere team,” said Michael V Novinski, president and CEO of Emisphere.
